Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | EYA2 | O00167 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28546389 | 0.84 | HDAC6 (0.35) | HDAC6HDAC1HDAC2L3MBTL1CA14 | |
| SCHEMBL28246198 | 0.81 | HDAC6 (0.37) | HDAC6HDAC1HDAC2L3MBTL1CA14 | |
| SCHEMBL24186853 | 0.79 | HDAC6 (0.37) | HDAC6HDAC1HDAC2L3MBTL1DGAT1 | |
| SCHEMBL4989700 | 0.79 | TDP1 (0.35) | EYA2APPACETDP1 | |
| SCHEMBL7719558 | 0.77 | HDAC6 (0.38) | HDAC6HDAC1HDAC2L3MBTL1DGAT1 | |
| SCHEMBL78691 | 0.77 | CA14 (0.41) | HDAC6HDAC1HDAC2L3MBTL1DGAT1 | |
| SCHEMBL13017451 | 0.76 | CA14 (0.42) | HDAC6HDAC1HDAC2L3MBTL1DGAT1 | |
| SCHEMBL8768722 | 0.75 | HDAC6 (0.39) | HDAC6HDAC1HDAC2L3MBTL1DGAT1 | |
| SCHEMBL336495 | 0.75 | HDAC6 (0.37) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL30792573 | 0.74 | CA14 (0.37) | HDAC6HDAC1HDAC2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012466-A1 | COLCHICINE NEOGLYCOSIDES AND METHODS FOR THEIR SYNTHESIS AND USE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-10 | — | — | US | disclosed |
| US-8232254-B2 | Colchicine glycosylated to include a sugar moiety on a methoxyamino-appended colchicine; cytolysis equivalent to paclitaxel and doxorubicin; stabilizers of tubulin formation; anticarcinogenic -arthritic agents; Mediterranean fever, amyloidosis, scleroderma, irritable bowel syndrome or gout | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-07-31 | — | — | US | disclosed |
| US-20080171787-A1 | COLCHICINE NEOGLYCOSIDES AND METHODS FOR THEIR SYNTHESIS AND USE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171787-A1 | COLCHICINE NEOGLYCOSIDES AND METHODS FOR THEIR SYNTHESIS AND USE | TUBB6, TUBB, TUBA1C | HDAC6 179/4885HDAC1 1804/4885HDAC2 3338/4885 |
| US-20130012466-A1 | COLCHICINE NEOGLYCOSIDES AND METHODS FOR THEIR SYNTHESIS AND USE | TUBB6, TUBB, TUBA1C | HDAC6 179/4885HDAC1 1804/4885HDAC2 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.